Therapeutic effects of a novel tylophorine analog, NK-007, on collagen-induced arthritis through suppressing tumor necrosis factor α production and Th17 cell differentiation

Arthritis and Rheumatism

Volumn 64, Issue 9, 2012, Pages 2896-2906

  Wen, Ti ^a   Li, Yangguang ^a   Wu, Meng ^a   Sun, Xiaolin ^b   Bao, Xiucong ^a   Lin, Yuquan ^a   Hao, Jianlei ^a   Han, Lin ^a   Cao, Guangchao ^a   Wang, Ziwen ^a   Liu, Yuxiu ^a   Wu, Zhenzhou ^a   Hong, Zhangyong ^a   Wang, Puyue ^a   Zhao, Liqing ^a   Li, Zhanguo ^b   Wang, Qingmin ^a   Yin, Zhinan ^a  

^a NANKAI UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; COLLAGEN; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR ALPHA; NK 007; TUMOR NECROSIS FACTOR ALPHA; TYLOPHORINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL LINE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPLEEN CELL; STAINING; TH17 CELL; WESTERN BLOTTING;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CELL DIFFERENTIATION; CELL LINE; INDOLIZINES; INTERLEUKIN-17; MALE; MICE; MICE, INBRED DBA; PHENANTHRENES; RNA STABILITY; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865635857     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34528     Document Type: Article

References (46)

1. Zwerina J, Redlich K, Schett G, Smolen JS,. Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann N Y Acad Sci 2005; 1051: 716-29.
2. McInnes IB, Schett G,. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429-42.
3. Choy EH, Panayi GS,. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.
4. Feldmann M, Maini RN,. Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163-96.
5. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11.
6. Moreland LW,. Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998; 24: 579-91.
7. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
8. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614-24.
9. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al, for the 990757 Study Group. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003; 48: 927-34.
10. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al, for the CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817-29.
11. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97.
12. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42: 963-70.
13. Hot A, Miossec P,. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann Rheum Dis 2011; 70: 727-32.
14. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198: 1951-7.
15. Lubberts E, Koenders MI, van den Berg WB,. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005; 7: 29-37.
16. Lubberts E,. The role of IL-17 and family members in the pathogenesis of arthritis. Curr Opin Investig Drugs 2003; 4: 572-7.
17. + Th cells that cause autoimmune arthritis. J Exp Med 2007; 204: 41-7.
18. Korn T, Bettelli E, Oukka M, Kuchroo VK,. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485-517.
19. McGeachy MJ, Cua DJ,. Th17 cell differentiation: the long and winding road. Immunity 2008; 28: 445-53.
20. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996; 183: 2593-603.
21. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-β and TNF-α, by human macrophages. J Immunol 1998; 160: 3513-21.
22. Katz Y, Nadiv O, Beer Y,. Interleukin-17 enhances tumor necrosis factor α-induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts: a possible role as a "fine-tuning cytokine" in inflammation processes. Arthritis Rheum 2001; 44: 2176-84.
23. Chabaud M, Fossiez F, Taupin JL, Miossec P,. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998; 161: 409-14.
24. Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK, et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001; 167: 1004-13.
25. Lubberts E, Joosten LA, van de Loo FA, Schwarzenberger P, Kolls J, van den Berg WB,. Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res 2002; 51: 102-4.
26. Shahrara S, Pickens SR, Dorfleutner A, Pope RM,. IL-17 induces monocyte migration in rheumatoid arthritis. J Immunol 2009; 182: 3884-91.
27. You X, Pan M, Gao W, Shiah HS, Tao J, Zhang D, et al. Effects of a novel tylophorine analog on collagen-induced arthritis through inhibition of the innate immune response. Arthritis Rheum 2006; 54: 877-86.
28. Wen T, Wu M, Li Y, Chen X, Han L, Bao X, et al. A novel tylophorine analog NK-007 ameliorates colitis through inhibition of innate immune responses. Int Immunopharmacol. In press.
29. Brand DD, Latham KA, Rosloniec EF,. Collagen-induced arthritis. Nat Protoc 2007; 2: 1269-75.
30. Garcia S, Bodano A, Gonzalez A, Forteza J, Gomez-Reino JJ, Conde C,. Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice. Arthritis Res Ther 2006; 8: R14.
31. Song K, Li Q, Peng YB, Li J, Ding K, Chen LJ, et al. Silencing of hHS6ST2 inhibits progression of pancreatic cancer through inhibition of Notch signalling. Biochem J 2011; 436: 271-82.
32. Johnson CR, Kitz D, Little JR,. A method for the derivation and continuous propagation of cloned murine bone marrow macrophages. J Immunol Methods 1983; 65: 319-32.
33. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77-92.
34. Reisch N, Engler A, Aeschlimann A, Simmen BR, Michel BA, Gay RE, et al. DREAM is reduced in synovial fibroblasts of patients with chronic arthritic pain: is it a suitable target for peripheral pain management? Arthritis Res Ther 2008; 10: R60.
35. 2-chain expression. J Immunol 2000; 164: 3056-64.
36. Veldhoen M, Hirota K, Christensen J, O'Garra A, Stockinger B,. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 2009; 206: 43-9.
37. Pan M, Kang I, Craft J, Yin Z,. Resistance to development of collagen-induced arthritis in C57BL/6 mice is due to a defect in secondary, but not in primary, immune response. J Clin Immunol 2004; 24: 481-91.
38. Hitti E, Iakovleva T, Brook M, Deppenmeier S, Gruber AD, Radzioch D, et al. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol Cell Biol 2006; 26: 2399-407.
39. Carballo E, Lai WS, Blackshear PJ,. Feedback inhibition of macrophage tumor necrosis factor-α production by tristetraprolin. Science 1998; 281: 1001-5.
40. Sanduja S, Blanco FF, Dixon DA,. The roles of TTP and BRF proteins in regulated mRNA decay. Wiley Interdiscip Rev RNA 2011; 2: 42-57.
41. Miossec P,. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy [review]. Arthritis Rheum 2003; 48: 594-601.
42. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004; 50: 650-9.
43. Nakae S, Nambu A, Sudo K, Iwakura Y,. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003; 171: 6173-7.
44. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000; 164: 2832-8.
45. Hashizume M, Hayakawa N, Mihara M,. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17. Rheumatology (Oxford) 2008; 47: 1635-40.
46. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103: 1345-52.